Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC decreased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 198,429 shares of the biopharmaceutical company’s stock after selling 13,606 shares during the period. Emerald Advisers LLC owned approximately 0.30% of Celldex Therapeutics worth $7,344,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in CLDX. Arizona State Retirement System increased its position in Celldex Therapeutics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock valued at $601,000 after acquiring an additional 325 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 638 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the period. Principal Financial Group Inc. lifted its holdings in Celldex Therapeutics by 10.0% in the first quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock worth $552,000 after purchasing an additional 1,194 shares during the period. Finally, Fisher Asset Management LLC increased its stake in Celldex Therapeutics by 6.2% during the 4th quarter. Fisher Asset Management LLC now owns 21,812 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 1,274 shares during the period.

Insider Buying and Selling

In other Celldex Therapeutics news, VP Elizabeth Crowley sold 30,000 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $34.87, for a total transaction of $1,046,100.00. Following the sale, the vice president now directly owns 9,074 shares of the company’s stock, valued at approximately $316,410.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, VP Elizabeth Crowley sold 30,000 shares of Celldex Therapeutics stock in a transaction on Friday, June 14th. The stock was sold at an average price of $34.87, for a total transaction of $1,046,100.00. Following the transaction, the vice president now owns 9,074 shares in the company, valued at $316,410.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Samuel Bates Martin sold 17,172 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $35.42, for a total value of $608,232.24. Following the transaction, the chief financial officer now directly owns 28,125 shares in the company, valued at $996,187.50. The disclosure for this sale can be found here. Company insiders own 3.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CLDX. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Monday, August 12th. Wells Fargo & Company upped their target price on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Stifel Nicolaus began coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 price target on the stock. Wolfe Research started coverage on Celldex Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, July 30th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $63.83.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX opened at $43.76 on Friday. The company has a market capitalization of $2.90 billion, a PE ratio of -15.35 and a beta of 1.56. The stock has a fifty day moving average of $37.57 and a 200-day moving average of $38.96. Celldex Therapeutics, Inc. has a one year low of $22.11 and a one year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. The business had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. As a group, research analysts forecast that Celldex Therapeutics, Inc. will post -2.5 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.